Parkinson’s UK awards ICL £100,000 to develop small drugs for Parkinson’s disease
The neurodegenerative condition currently affects around 153,000 people in the UK
Read More
Tag: GPNMB
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
